Pay in 4 interest-free payments of $6.87 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Doering, C
Determinants of weight gain during adjuvant endocrine therapy and association of such weight gain with recurrence in long-term breast cancer survivors
In the Stanford cohort, the AUC reached 0.93 for our panel versus 0.77 for IBP4/SHBG
Decisions on appropriate use may be made taking into consideration the glycemic parameters together with the status of CV and renal comorbidity and clinically relevant considerations, such as risk of hypoglycemia and weight gain
US$ 28.65
US$ 26.06
US$ 22.45
US$ 22.44
US$ 23.53
US$ 25.50
US$ 25.96
US$ 22.73
